Related Experiment Videos
Population-based drug-induced agranulocytosis
Luisa Ibáñez1, Xavier Vidal, Elena Ballarín
1Fundació Institut Català de Farmacologia, Universitat Autònoma de Barcelona, Clinical Pharmacology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Archives of Internal Medicine
|April 27, 2005
Summary
Agranulocytosis is a rare but serious condition. A small number of drugs, including ticlopidine hydrochloride and calcium dobesilate, are responsible for most cases, while newer medications appear to pose a lower risk.
Area of Science:
- Hematology
- Pharmacovigilance
- Epidemiology
Background:
- Since the 1980s, numerous new drugs have entered therapeutic use, necessitating updated risk assessments for agranulocytosis.
- Previous studies highlighted the association between certain medications and agranulocytosis, a severe blood disorder.
Purpose of the Study:
- To investigate the current incidence and risk factors for agranulocytosis in Barcelona.
- To identify specific drugs associated with agranulocytosis and quantify their associated risks.
Main Methods:
- A case-control study was conducted in Barcelona, Spain, involving 17 hematology units.
- Data from 177 community-acquired agranulocytosis cases were compared with 586 matched controls over 78.73 million person-years.
- Medication history was analyzed to determine drug-associated risks.
Main Results:
- The annual incidence of agranulocytosis was 3.46 per million, increasing with age.
- Ticlopidine hydrochloride (OR, 103.23) and calcium dobesilate (OR, 77.84) showed the strongest association with agranulocytosis.
- Antithyroid drugs, dipyrone, and spironolactone also presented significant risks, alongside other medications accounting for 68.6% of cases.
Conclusions:
- Agranulocytosis, though rare, carries a significant fatality rate (7.0%).
- A limited number of drugs are implicated in the majority of agranulocytosis cases.
- The study suggests a reassuring safety profile for many newly marketed drugs regarding agranulocytosis risk.